Aripiprazole Tablet
Product Images NDC 68788-7749

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68788-7749). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure4 (Aripiprazole Fig4)

A forest plot chart titled 'Aripiprazole Fold Change and 90% CI' showing pharmacokinetic changes relative to reference across special populations. It compares AUC and Cmax for groups including CYP2D6 poor vs. extensive metabolizers, female vs. male, age groups, and various degrees of hepatic and renal impairment, illustrating the fold change with 90% confidence intervals.*

FDA Label Image

Figure5 (Aripiprazole Fig5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' displaying fold change in AUC and Cmax relative to reference, comparing effects of CYP2D6 metabolism status, gender, age groups, hepatic impairment severity, and severe renal impairment on drug levels.*

FDA Label Image

Structure (Aripiprazole Struct)

Chemical structure of aripiprazole, showing its molecular framework with chlorine atoms, piperazine ring, and quinolinone moiety as depicted in the image.*

FDA Label Image

Aripiprazole Tablets Usp 5mg (Aripiprazole2mg)

Label for Aripiprazole Tablets USP 5mg by Preferred Pharmaceuticals, Inc. The label is bright yellow with bold black text showing the drug name, strength, and dosage form. It includes usage directions in English and Spanish, storage instructions, and cautions about prescription use. The manufacturer is identified as Torrent Pharmaceuticals Limited. Barcodes and QR codes are also present on the label.*

FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax. The chart compares changes relative to a reference without interacting drugs, listing drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

A scatter plot showing the effect of various drugs on the pharmacokinetics of Aripiprazole. The graph plots fold change and 90% confidence intervals for AUC and Cmax relative to a reference without interacting drugs, listing inhibitors, inducers, and other drugs against Aripiprazole exposure.*

FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

A forest plot titled 'Effect of Aripiprazole on other Drugs' showing fold change and 90% confidence intervals for the pharmacokinetics (PK) of various drugs including CYP2D6 and CYP2C9 substrates, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The x-axis depicts change relative to reference (without interacting drug) ranging from 0.0 to 3.0, with plotted points mostly clustered near 1.0 indicating minimal fold change.*

FDA Label Image

Figure6 (Aripiprazole Fig 06)

A Kaplan-Meier survival curve graph showing the proportion of subjects with relapse over time for two groups: Aripiprazole and Placebo. The x-axis represents the number of subjects at risk at various time points, while the y-axis shows the proportion with relapse. Aripiprazole group is represented by a solid blue line and the placebo group by a dashed red line.*

FDA Label Image

Aripiprazole_fig_07 (Aripiprazole Fig 07)

A line graph comparing the proportion of subjects experiencing relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from 0 to 182, and the y-axis shows proportion relapse from 0 to 1. Aripiprazole is represented by a solid blue line, and placebo by a dashed red line. Below the x-axis, a table lists the number of subjects at risk for each group at various time points.*

FDA Label Image

Aripiprazole_fig_08 (Aripiprazole Fig 08)

A line graph comparing the proportion with relapse over time between two groups: Aripiprazole and placebo. The x-axis represents days from randomization, ranging from 0 to 364, and the y-axis represents the proportion with relapse from 0.0 to 1.0. Numbers of subjects at risk are shown below the x-axis for each group over time. The Aripiprazole group is plotted with a solid blue line, and the placebo group with a dashed red line, showing a higher relapse proportion for placebo across the study duration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.